GreenLight Ventures

GreenLight Biosciences is a biotechnology company specializing in the development and manufacture of RNA-based products for human health and agriculture. The company utilizes a proprietary cell-free RNA production platform designed to produce high-quality RNA at a significantly lower cost and larger scale than traditional fermentation methods. In human health, GreenLight focuses on mRNA vaccines and therapeutics, with a pipeline including programs for COVID-19, influenza, shingles, and sickle cell disease. Its agricultural division develops RNAi-based biopesticides that provide targeted pest control with minimal environmental impact. Formerly a public company, GreenLight was taken private in 2023 by a consortium led by Fall Line Capital.